Your Source for Venture Capital and Private Equity Financings

Umoja Biopharma Scores $210M Series B Round

SEATTLE, WA, Umoja Biopharma today announced the completion of an oversubscribed $210 million Series B financing.
Umoja Biopharma, an oncology company leveraging its proprietary integrated technologies to reprogram immune cells in vivo to create next-generation immunotherapies for the treatment of solid tumors and hematologic malignancies, today announced the completion of an oversubscribed $210 million Series B financing. The proceeds will enable Umoja to continue development of its integrated technologies, advance its product candidates based on CAR T-cell adapter-mediated tumor-targeting (TumorTag) and the in vivo modification of immune cells (VivoVec and RACR/CAR) into clinical development, and build internal manufacturing capabilities to support preclinical and clinical development of its pipeline programs.

The financing was co-led by SoftBank Vision Fund 2 and Cormorant Asset Management with participation from new investors, including RTW Investments, LP; Temasek; Presight Capital (the international venture arm of Christian Angermayer's Apeiron Investment Group); Caas Capital; and an investment fund associated with SVB Leerink. They were joined by all the company's existing investors: MPM Capital, DCVC Bio, Qiming Venture Partners USA, Casdin Capital, The Emerson Collective, and Alexandria Venture Investments.

Umoja Biopharma is a preclinical stage company advancing an entirely new approach to immunotherapy designed to retool a patient's immune system in vivo. Founded based on pioneering work performed at Seattle Children's Research Institute and Purdue University, Umoja's novel approach is powered by integrated cellular immunotherapy technologies comprising the VivoVec in vivo delivery platform, the RACR/CAR in vivo cell expansion/control platform and the TumorTag targeting platform. Designed from the ground up to work together, these platforms are being developed to create and harness a powerful immune response in the body to directly, safely and controllably attack cancer. Umoja believes that its approach can provide broader access to the most advanced immunotherapies and enable more patients to live better, fuller lives.
(c)2011-2020 by Massinvestor, Inc. For contact info, please check out our about page.
>> Click here for in-depth research on 9,000 startups and 5,000 VC investors

Featured Reading